Envista Holdings Co. (NYSE:NVST) Given Average Recommendation of “Hold” by Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have been assigned a consensus rating of “Hold” from the fourteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.08.

A number of brokerages recently issued reports on NVST. Morgan Stanley set a $16.00 price objective on shares of Envista in a report on Tuesday, April 15th. New Street Research set a $19.00 price target on shares of Envista in a report on Thursday, March 6th. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research note on Thursday, March 6th. Wells Fargo & Company set a $19.00 target price on Envista in a research report on Saturday, March 8th. Finally, JPMorgan Chase & Co. reduced their price target on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th.

Hedge Funds Weigh In On Envista

Several institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. grew its stake in shares of Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares during the period. Brickwood Asset Management LLP acquired a new stake in Envista in the fourth quarter valued at approximately $40,037,000. Norges Bank bought a new stake in shares of Envista during the fourth quarter valued at approximately $38,052,000. Pzena Investment Management LLC raised its position in shares of Envista by 160.7% during the first quarter. Pzena Investment Management LLC now owns 2,294,257 shares of the company’s stock worth $39,599,000 after purchasing an additional 1,414,080 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Envista by 19.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after purchasing an additional 1,089,923 shares in the last quarter.

Envista Stock Performance

NYSE NVST opened at $17.77 on Friday. The firm’s fifty day moving average price is $16.50 and its two-hundred day moving average price is $19.00. The stock has a market cap of $3.01 billion, a PE ratio of -2.74, a PEG ratio of 1.27 and a beta of 0.97. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00.

Envista (NYSE:NVST) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Envista’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS. On average, equities analysts expect that Envista will post 1 EPS for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.